Mod GRF 1-29 vs Cortexin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Cortexin
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | Cortexin |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Contains a mixture of neuropeptides and amino acids that support neuronal metabolism, provide neuroprotection, and enhance synaptic transmission. Specific mechanisms not fully characterized. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Clinical protocols: 10mg intramuscularly once daily for 10-20 days. May be repeated after 3-6 month interval. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Intramuscular injection. Comes as lyophilized powder requiring reconstitution. Treatment given in courses rather than continuously. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Generally well-tolerated. May cause injection site reactions or mild allergic responses in sensitive individuals. |
| Best For |
What They Have in Common
Both Mod GRF 1-29 and Cortexin are commonly used for: